SageView Advisory Group
EWTX icon

SageView Advisory Group’s Edgewise Therapeutics EWTX Stock Holding History

SageView Advisory Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11
Closed -$273 – 1180
2025
Q4 		$273 Buy
+11
New +$221 ﹤0.01% 2496

Other funds holding EWTX

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SageView Advisory Group's EWTX Position: Q1 2026 in Review

SageView Advisory Group sold out of Edgewise Therapeutics (EWTX) in Q1 2026, closing a stake of 11 shares — an estimated $273 sold.

SageView Advisory Group first reported a position in EWTX in Q4 2025 and held it in 1 quarter. The position peaked at $273 in Q4 2025. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • SageView Advisory Group reported no remaining Edgewise Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 11 Edgewise Therapeutics shares in Q1 2026, an estimated $273.
  • SageView Advisory Group first reported a position in Edgewise Therapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Edgewise Therapeutics position peaked at $273 in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.